• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma - 27 Studies Found

Completed : A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
: Cutaneous T-Cell Lymphoma
: 2008-08-29
: Drug: Enzastaurin 1125 mg loading dose then 500 mg, oral, daily, until disease progression
Completed : Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
: Cutaneous T-Cell Lymphoma
: 2008-10-22
: Drug: Tazarotene Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase
Completed : Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
: Cutaneous T-cell Lymphoma
: 2014-02-11
:
  • Drug: Romidepsin Other Names:

Withdrawn : Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
: Cutaneous T-cell Lymphoma (CTCL)
: 2013-04-24
: Drug: Sirolimus 0.1% Ointment Sirolimus 0.1% ointment will be applied topically to all affected areas of
Active, not recruiting : Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
: Cutaneous T Cell Lymphoma
: 2012-07-15
:
  • Drug: Topical resiquimod 0.06%

Completed : Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
: Cutaneous T-Cell Lymphoma
: 2006-03-23
:
  • Drug: bexarotene
  • Device: photopheresis

Completed : A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
: Cutaneous T-cell Lymphoma
: 2005-03-24
: Drug: romidepsin (depsipeptide, FK228) Study patients received romidepsin at a dose of 14 mg/m^2 intrave
Completed : Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
: Cutaneous T-Cell Lymphoma
: 2015-10-29
: Biological: IPH4102
Completed : Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
: Cutaneous T Cell Lymphoma
: 2015-09-06
: Drug: dimethylfumarate dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design i
Completed : Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)
: Refractory Cutaneous T-cell Lymphoma
: 2009-11-03
:
  • Drug: bexarotene 150 mg/m2/day

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.